<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03115047</url>
  </required_header>
  <id_info>
    <org_study_id>2017-7124</org_study_id>
    <nct_id>NCT03115047</nct_id>
  </id_info>
  <brief_title>Shivering Treatment After Cesarean Delivery: Meperidine vs. Dexmedetomidine</brief_title>
  <official_title>Traitement Des Frissons Lors de la césarienne Sous anesthésie péridurale Durant le Travail - un Essai Clinique randomisé Comparant la dexmédétomidine et la mépéridine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparing two treatments for shivering after cesarean delivery for labor dystocia under
      epidural anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a double blinded randomized control trial.

      Study population: parturients undergoing a cesarean delivery for labor dystocia under
      epidural anesthesia experiencing shivering grade III or IV on the standardized shivering
      scale of Crossley and Mahajan

      Experimental group: dexmedetomidine 0.35 mcg/kg IV in 2 minutes

      Control group: meperidine 0.35 mg/kg IV in 2 minutes

      Primary outcome : Time to stop level III and IV shivering on the Crossley and Mahajan
      standardized shivering scale after the administration of the study drug

      Secondary outcome: Response rate, incidence of nausea, vomiting, hypotension, bradycardia,
      maternal satisfaction and a cost-benefit analysis.

      The hypothesis is that dexmedetomidine will act faster, will have a superior response rate
      with less adverse effects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2017</start_date>
  <completion_date type="Anticipated">April 24, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 24, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Comparing two groups: experimental (dexmedetomidine) versus control (meperidine)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blinded randomized study: meperidine and dexmedetomidine will be prepared at the hospital pharmacy in a 10 mL seringue with equivalent dilution in order to gave mL/kg.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Stop time</measure>
    <time_frame>15 minutes</time_frame>
    <description>Time to stop class III or IV shivering on the Crossley and Mahajan standardized shivering scale after the administration of the study drug (meperidine versus dexmedetomidine)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse effects</measure>
    <time_frame>24 hours</time_frame>
    <description>sedation, nausea, vomiting, hypotension and bradycardia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maternal satisfaction</measure>
    <time_frame>at 24 hours</time_frame>
    <description>satisfaction (yes or no) regarding experience with study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>15 minutes</time_frame>
    <description>percentage of patient responding when the drug is given</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost benefice analysis</measure>
    <time_frame>24 hours</time_frame>
    <description>comparing cost of the drug</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cesarean Section Complications</condition>
  <arm_group>
    <arm_group_label>dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unique dose of dexmedetomidine injection:
intravenous injection
0.35 mcg/kg
in two minutes
if shivering 5 minutes after delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meperidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Unique dose of meperidine injection:
intravenous injection
0.35 mg/kg
in two minutes
if shivering 5 minutes after delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine Injection</intervention_name>
    <description>0.35 mcg/kg intravenous in 2 minutes if shivering 5 minutes after delivery</description>
    <arm_group_label>dexmedetomidine</arm_group_label>
    <other_name>precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meperidine Injection</intervention_name>
    <description>0.35 mg/kg intravenous in 2 minutes if shivering 5 minutes after delivery</description>
    <arm_group_label>meperidine</arm_group_label>
    <other_name>demerol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Term &gt; 37 weeks

          -  American Society of Anesthesiologists Physical Status (ASA PS) I, II

          -  Weight &lt; 115 kg

          -  Functional epidural in situ

          -  In labor requiring cesarean delivery

          -  Class III or IV shivering on the Crossley and Mahajan standardized shivering scale
             between five minutes after the baby's birth to the end of the cesarean section

        Exclusion Criteria:

          -  Refusal of the patient and/or the anesthesiologist

          -  Misunderstanding of the protocol

          -  Known allergy or contraindication to one of the study drugs

          -  Emergency cesarean delivery

          -  American Society of Anesthesiologists Physical Status III, IV, V

          -  Severe heart, liver or kidney disease,

          -  Preeclampsia

          -  Patient taking monoamine oxydase inhibitors

          -  Sleep apnea

          -  General anesthesia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Parturient, after cesarean delivery</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Lavoie, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Lavoie, MD, FRCPC</last_name>
    <phone>514-890-8358</phone>
    <email>anne.lavoie@umontreal.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gabriel Paquin-Lanthier, MD</last_name>
    <phone>514-445-2383</phone>
    <email>gabriel.paquin-lanthier@umontreal.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel Paquin-Lanthier, MD</last_name>
      <phone>514-445-2383</phone>
      <email>gabriel.paquin-lanthier@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>Anne Lavoie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Crowley LJ, Buggy DJ. Shivering and neuraxial anesthesia. Reg Anesth Pain Med. 2008 May-Jun;33(3):241-52. doi: 10.1016/j.rapm.2007.11.006. Review.</citation>
    <PMID>18433676</PMID>
  </reference>
  <reference>
    <citation>De Witte J, Sessler DI. Perioperative shivering: physiology and pharmacology. Anesthesiology. 2002 Feb;96(2):467-84. Review.</citation>
    <PMID>11818783</PMID>
  </reference>
  <reference>
    <citation>Kranke P, Eberhart LH, Roewer N, Tramèr MR. Pharmacological treatment of postoperative shivering: a quantitative systematic review of randomized controlled trials. Anesth Analg. 2002 Feb;94(2):453-60, table of contents.</citation>
    <PMID>11812718</PMID>
  </reference>
  <reference>
    <citation>Abdel-Ghaffar HS, Mohamed SA, Fares KM, Osman MA. Safety and Efficacy of Dexmedetomidine in Treating Post Spinal Anesthesia Shivering: A Randomized Clinically Controlled Dose-Finding Trial. Pain Physician. 2016 May;19(4):243-53.</citation>
    <PMID>27228512</PMID>
  </reference>
  <reference>
    <citation>Tsai YC, Chu KS. A comparison of tramadol, amitriptyline, and meperidine for postepidural anesthetic shivering in parturients. Anesth Analg. 2001 Nov;93(5):1288-92.</citation>
    <PMID>11682416</PMID>
  </reference>
  <reference>
    <citation>Mittal G, Gupta K, Katyal S, Kaushal S. Randomised double-blind comparative study of dexmedetomidine and tramadol for post-spinal anaesthesia shivering. Indian J Anaesth. 2014 May;58(3):257-62. doi: 10.4103/0019-5049.135031.</citation>
    <PMID>25024466</PMID>
  </reference>
  <reference>
    <citation>Saito T, Sessler DI, Fujita K, Ooi Y, Jeffrey R. Thermoregulatory effects of spinal and epidural anesthesia during cesarean delivery. Reg Anesth Pain Med. 1998 Jul-Aug;23(4):418-23.</citation>
    <PMID>9690596</PMID>
  </reference>
  <reference>
    <citation>Crossley AW, Mahajan RP. The intensity of postoperative shivering is unrelated to axillary temperature. Anaesthesia. 1994 Mar;49(3):205-7.</citation>
    <PMID>8147511</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>July 21, 2017</last_update_submitted>
  <last_update_submitted_qc>July 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Meperidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

